Acyline
Appearance
![]() | |
Clinical data | |
---|---|
Other names | MER-104 |
Routes of administration | Subcutaneous injection[1][2] |
Drug class | GnRH antagonist |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C80H102ClN15O14 |
Molar mass | 1533.24 g·mol−1 |
3D model (JSmol) | |
| |
|
Acyline (developmental code name MER-104) is a gonadotropin-releasing hormone analogue (GnRH analogue) and gonadotropin-releasing hormone antagonist (GnRH antagonist) which was never marketed.[1][2][3] It has been shown to suppress gonadotropin and testosterone levels in men.[1][2][3] Acyline is a peptide and under normal circumstances is not orally active.[3] For this reason, it has instead been administered by subcutaneous injection.[1][2]
See also
[edit]References
[edit]- ^ a b c d Herbst KL, Anawalt BD, Amory JK, Bremner WJ (July 2002). "Acyline: the first study in humans of a potent, new gonadotropin-releasing hormone antagonist". J. Clin. Endocrinol. Metab. 87 (7): 3215–20. doi:10.1210/jcem.87.7.8675. hdl:1773/4394. PMID 12107227.
- ^ a b c d Herbst KL, Coviello AD, Page S, Amory JK, Anawalt BD, Bremner WJ (December 2004). "A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men". J. Clin. Endocrinol. Metab. 89 (12): 5959–65. doi:10.1210/jc.2003-032123. hdl:1773/4325. PMID 15579744.
- ^ a b c Amory JK, Leonard TW, Page ST, O'Toole E, McKenna MJ, Bremner WJ (August 2009). "Oral administration of the GnRH antagonist acyline, in a GIPET-enhanced tablet form, acutely suppresses serum testosterone in normal men: single-dose pharmacokinetics and pharmacodynamics". Cancer Chemother. Pharmacol. 64 (3): 641–5. doi:10.1007/s00280-009-1038-1. PMC 2721900. PMID 19479252.